Clinical Trial

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

VANCOUVER, BC, Jan. 6, 2025 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech…

12 months ago

Stroke Detection Innovator Wellumio Expands into the U.S. Market

Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster,…

12 months ago

PBS Biotech Expands Leadership Team and Secures $17 Million in Growth Capital to Accelerate Delivery of Next Generation Cell and Regenerative Therapies

Proceeds from the financing will be used to broaden and improve the company's offerings and for operational expansion across facilities,…

12 months ago

Why Diversity in Clinical Trials Is So Important

NORTHAMPTON, MA / ACCESSWIRE / January 6, 2025 / Clinical trials are essential for the development of health care products,…

12 months ago

Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash

Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

12 months ago

Biofourmis Selected by AdventHealth to Support “Whole-Person Care” With New Acute Care-at Home Program

NASHVILLE, Tenn.--(BUSINESS WIRE)--Biofourmis, a leading global technology-enabled care delivery company, and AdventHealth, have agreed to collaborate on a continuum-wide remote…

12 months ago

Frontage Announces Co-CEO Promotions

EXTON, PA / ACCESSWIRE / January 6, 2025 / Frontage Holdings Corporation today announced that Dr. Abdul Mutlib has decided…

12 months ago

SterileCare Inc. Reaches Key Enrollment Milestone in Innovative Catheter Lock Solution Trial

dicentra congratulates SterileCare on achieving a significant milestone in their innovative catheter lock solution clinical trial, with 20 patients enrolled…

12 months ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development…

12 months ago

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

12 months ago